MENU
CHRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Coherus BioSciences (CHRS) Ownership - Who owns Coherus BioSciences?

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer... Show more

Industry: #Biotechnology

Profile

Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
129.8M
P/E Ratio
4.48
Total Cash
125.99M
Projected Growth
N/A
Total Debt
269.9M
Revenue
266.96M
Risk (Beta)
1.07
Dividend Yield
N/A
Total Cash/Share
1.09
Total Debt/Equity
N/A
Revenue/Share
2.32 USD as % of share price

Fundamentals

CHRS
Capitalization
130M
P/E Ratio
4.48
Risk (Beta)
1.07
Dividend Yield
N/A
Total Cash
126M
Total Cash/Share
1.09
Total Debt
270M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
2.32%
Revenue
267M
ROE
N/A
Book Value
-131.99M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
0.25
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
12K
Current Ratio
1.21
Current Revenue Per Employee
237473.69
Dividends Per Share - Security
N/A
EBITDA
60.9M
Float
N/A
Float - Current
N/A
Gross Income Margin
37.47
Revenue To Assets
5.29
Shares Held By Institutions
120M
Shares Outstanding - Current
116M
Total Liabilities
581M
Total Volume MTD
N/A
Value
-1
Gain YTD
-18.841
View a ticker or compare two or three
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a maker of biologic therapeutics for oncology and inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Twin Dolphin Drive
Phone
+1 650 649-3530
Employees
306
Web
https://www.coherus.com